Cairn Surgical's Breast Cancer Locator System Meets Primary Endpoint in Pivotal Trial, Reduces Positive Margin Rates

Key Takeaways

• Cairn Surgical’s Breast Cancer Locator System met its primary endpoint in pivotal trial with lower positive margin rates than conventional wire localization
• The investigational medical device could improve surgical precision for breast cancer patients by reducing the need for additional surgeries
• Results position the company for potential regulatory submission and commercialization of the BCL System

---

Cairn Surgical Reports Successful Pivotal Trial for Breast Cancer Surgery Device

Cairn Surgical, Inc., a Seattle-based medical technology company, announced positive results from its pivotal clinical trial evaluating the investigational Breast Cancer Locator (BCL™) System. The study successfully met its primary endpoint, demonstrating a lower positive margin rate (PMR) across all cancer types compared to conventional wire localization methods.

Improved Surgical Precision for Breast Cancer Treatment

The BCL System represents a significant advancement in breast cancer surgical technology, designed to enhance precision during tumor removal procedures. Positive surgical margins occur when cancer cells remain at the edge of removed tissue, often requiring additional surgeries that can delay treatment and increase patient stress.

Conventional wire localization has been the standard method for guiding surgeons to tumor locations, but the technology has limitations in accuracy and patient comfort. Cairn Surgical’s innovative approach aims to address these challenges through improved localization technology.

Market Impact and Clinical Significance

The successful trial results position Cairn Surgical for potential regulatory submissions and future commercialization of the BCL System. Reducing positive margin rates could significantly impact patient outcomes by minimizing the need for re-excision surgeries, which occur in approximately 20-25% of breast-conserving surgeries using current methods.

The medical device market for breast cancer surgical tools continues to grow as healthcare providers seek technologies that improve patient outcomes while reducing healthcare costs. Enhanced surgical precision tools like the BCL System address critical unmet needs in oncological care.

Next Steps for Regulatory Approval

With positive pivotal trial data, Cairn Surgical is expected to pursue regulatory approval pathways. The company’s focus on making breast cancer surgery more precise aligns with healthcare trends toward personalized medicine and improved surgical outcomes.

---

Frequently Asked Questions

What is the Breast Cancer Locator System?

The BCL System is an investigational medical device developed by Cairn Surgical to improve surgical precision during breast cancer tumor removal by providing better localization compared to conventional wire methods.

When will the BCL System be available to patients?

The system is still investigational and requires regulatory approval. With successful pivotal trial results, Cairn Surgical may pursue regulatory submissions, though specific timelines have not been announced.

How does this compare to current breast cancer surgery methods?

The pivotal trial showed the BCL System achieved lower positive margin rates compared to conventional wire localization, potentially reducing the need for additional surgeries that occur in 20-25% of current procedures.

Related coverage

• Cobenfy meets endpoint in Bristol Myers Squibb’s Alzheimer’s psychosis trial
• Breast Cancer Statistics Worldwide: What the Data Shows
• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial